In recent trading session, TransCode Therapeutics Inc (NASDAQ:RNAZ) saw 1.06 million shares changing hands at last check today with its beta currently measuring 1.53. Company’s recent per share price level of $0.50 trading at -$0.03 or -5.30% at last check today assigns it a market valuation of $11.69M. That most recent trading price of RNAZ’s stock is at a discount of -13166.0% from its 52-week high price of $66.33 and is indicating a premium of 14.0% from its 52-week low price of $0.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 29.05 million shares which gives us an average trading volume of 7.24 million if we extend that period to 3-months.

TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information

Upright in the red during last session for losing -5.30%, in the last five days RNAZ remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $0.50 price level, adding 25.37% to its value on the day. TransCode Therapeutics Inc’s shares saw a change of -85.15% in year-to-date performance and have moved -3.75% in past 5-day. TransCode Therapeutics Inc (NASDAQ:RNAZ) showed a performance of -72.65% in past 30-days. Number of shares sold short was 0.34 million shares which calculate 0.15 days to cover the short interests.

TransCode Therapeutics Inc (RNAZ) estimates and forecasts

1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 300k for the same. Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -28.81% during past 5 years.

TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders

Insiders are in possession of 0.15% of company’s total shares while institution are holding 0.67 percent of that, with stock having share float percentage of 0.67%. Investors also watch the number of corporate investors in a company very closely, which is 0.67% institutions for TransCode Therapeutics Inc that are currently holding shares of the company.

On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Total Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025, the former fund manager was holding 2.83 shares of worth $1413.0 or 0.02% of the total outstanding shares. The later fund manager was in possession of 1.18 shares on Jan 31, 2025, making its stake of worth around $588.0 in the company or a holder of 0.01% of company’s stock.